{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/prescribing-information/spironolactone/","result":{"pageContext":{"chapter":{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone","depth":2,"htmlHeader":"<!-- begin field 385772de-5db0-4e08-a543-a71600db47d5 --><h2>Spironolactone</h2><!-- end field 385772de-5db0-4e08-a543-a71600db47d5 -->","summary":"","htmlStringContent":"<!-- begin item 3b9e8045-ec28-4c70-ba14-a71600db4876 --><!-- end item 3b9e8045-ec28-4c70-ba14-a71600db4876 -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a7b04286-3405-54e4-84ac-f5f665cb3217","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 2be1b6ec-ca58-44c0-a86f-a71a00cb7791 --><h3>Contraindications and cautions</h3><!-- end field 2be1b6ec-ca58-44c0-a86f-a71a00cb7791 -->","summary":"","htmlStringContent":"<!-- begin item dfa45254-e332-4005-b1b1-a71a00cb7880 --><!-- begin field 13a48012-d9cd-4a65-955a-a71a00cb7791 --><ul><li><strong>Do not prescribe spironolactone to people with:</strong><ul><li>Addison's disease.</li><li>Acute renal insufficiency, significant renal compromise, anuria.</li><li>Hyperkalaemia.</li></ul></li><li><strong>Prescribe spironolactone with caution to:</strong><ul><li>People with acute porphyrias.</li><li>Elderly people.</li></ul></li><li><strong>Note:</strong> spironolactone treatment should be stopped if the person becomes dehydrated due to vomiting and/or diarrhoea, as there is an increased risk of hyperkalaemia and renal failure.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">National Clinical Guideline Centre, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field 13a48012-d9cd-4a65-955a-a71a00cb7791 --><!-- end item dfa45254-e332-4005-b1b1-a71a00cb7880 -->","subChapters":[]},{"id":"8b9ce1bb-c3d6-5a43-a668-7ee5cc1d70da","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9b07f66f-7315-40a6-a8ed-a71a00cbb368 --><h3>Adverse effects</h3><!-- end field 9b07f66f-7315-40a6-a8ed-a71a00cbb368 -->","summary":"","htmlStringContent":"<!-- begin item c7b6a349-42f9-4fe5-9c62-a71a00cbb4d7 --><!-- begin field c27eff26-4b84-4244-849d-a71a00cbb368 --><ul><li><strong>Adverse effects of spironolactone include:</strong><ul><li>Acute renal failure.</li><li>Agranulocytosis, leucopenia, and thrombocytopenia </li><li>Alopecia.</li><li>Benign breast tumours, breast pain, gynaecomastia.</li><li>Changes in libido. </li><li>Confusion. </li><li>Dizziness.</li><li>Drowsiness. </li><li>Electrolyte disturbances, hyperkalaemia (discontinue if this occurs), hyponatraemia.</li><li>Gastrointestinal disturbances, nausea.</li><li>Hepatotoxicity. </li><li>Hypertrichosis. </li><li>Hyperuricaemia.</li><li>Leg cramps. </li><li>Malaise. </li><li>Menstrual disturbances.</li><li>Pruritis.</li><li>Rash, Stevens-Johnson syndrome.</li><li>Urticaria.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016o</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field c27eff26-4b84-4244-849d-a71a00cbb368 --><!-- end item c7b6a349-42f9-4fe5-9c62-a71a00cbb4d7 -->","subChapters":[]},{"id":"0683a598-3e87-59a1-9629-fc79236ba5e3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e8894ef4-e660-4706-9984-a71a00cbcd0c --><h3>Drug interactions</h3><!-- end field e8894ef4-e660-4706-9984-a71a00cbcd0c -->","summary":"","htmlStringContent":"<!-- begin item 710388aa-2fc1-4c7c-b0f0-a71a00cbce46 --><!-- begin field cb0bd79a-a32a-465d-82a9-a71a00cbcd0c --><ul><li><strong>Drug interactions with spironolactone include:</strong><ul><li>Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers — increased risk of severe hyperkalaemia with concurrent use.<ul><li>Prescribe the lowest possible doses of both drugs and monitor renal function closely.</li><li>Avoid concurrent use in people with marked renal impairment. </li><li>Should hyperkalaemia develop, spironolactone should be discontinued, and if necessary, active measures should be taken to reduce the serum potassium to normal.</li></ul></li><li>Antihypertensive drugs — hypotensive effect potentiated. </li><li>Ciclosporin, heparins, other potassium-sparing diuretics, potassium supplements, tacrolimus- concomitant use may result in severe hyperkalaemia. Trimethoprim/sulfamethoxazole (co-trimoxazole) — concomitant use may result in clinically significant hyperkalaemia.<ul><li>Should hyperkalaemia develop, spironolactone should be discontinued, and if necessary, active measures should be taken to reduce the serum potassium to normal.</li></ul></li><li>Aspirin and nonsteroidal anti-inflammatory drugs — attenuate the diuretic effect of spironolactone</li><li>Digoxin<strong> </strong>— spironolactone may increase serum concentrations of digoxin and interfere with serum digoxin assays. If digoxin dose needs to be adjusted, monitor the person carefully for signs of an enhanced or reduced digoxin effect.</li><li>Lithium — concurrent use can reduce excretion of lithium. Consider monitoring of plasma lithium concentrations.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016o</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field cb0bd79a-a32a-465d-82a9-a71a00cbcd0c --><!-- end item 710388aa-2fc1-4c7c-b0f0-a71a00cbce46 -->","subChapters":[]},{"id":"84880cc2-4b92-5c1d-8c6c-a9a355bec6e5","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field ff8e0157-0d81-4d1b-b093-a71a00cb8c11 --><h3>Dose and titration</h3><!-- end field ff8e0157-0d81-4d1b-b093-a71a00cb8c11 -->","summary":"","htmlStringContent":"<!-- begin item ba922067-ccc5-419c-af09-a71a00cb8d0f --><!-- begin field 3077de70-a3de-443f-8fef-a71a00cb8c11 --><ul><li><strong>Spironolactone is not currently licensed for the treatment of hypertension, so this is an off-label indication. Obtain and document informed consent.</strong><ul><li>If the person is already taking three antihypertensive drugs and blood pressure is not controlled (resistant hypertension), consider adding spironolactone if blood potassium level is 4.5 mmol/L or lower.</li><li>Prescribe low-dose spironolactone 25 mg once a day, to be taken with food.</li><li>Upward dose titration is not recommended for the treatment of hypertension alone.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field 3077de70-a3de-443f-8fef-a71a00cb8c11 --><!-- end item ba922067-ccc5-419c-af09-a71a00cb8d0f -->","subChapters":[]},{"id":"6b1ad054-4e09-590f-8451-c5fdb89397ed","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 0c6fc347-9466-43bf-861e-a71a00cba182 --><h3>Monitoring</h3><!-- end field 0c6fc347-9466-43bf-861e-a71a00cba182 -->","summary":"","htmlStringContent":"<!-- begin item 38fdf132-f585-453a-822c-a71a00cba2a2 --><!-- begin field 38919eff-8d7d-4d9a-8380-a71a00cba182 --><ul><li><strong>When using spironolactone as adjunctive therapy for resistant hypertension:</strong><ul><li>Measure renal function (serum creatinine and estimated glomerular filtration rate [eGFR]) and serum electrolytes (noting potassium levels) before starting spironolactone.<ul><li>Only prescribe spironolactone for people whose blood potassium level is 4.5 mmol/l or lower.</li><li>Use particular caution in people with a reduced eGFR because they have an increased risk of hyperkalaemia.</li></ul></li><li>Repeat these tests within 1 month of starting treatment.</li><li>Then, repeat monitoring: <ul><li>Monthly for a further 2 months, then every 3 months for 1 year, then every 6 months thereafter.</li><li>After any dose increase.</li></ul></li><li>For people who are at higher risk of hyperkalaemia or deteriorating renal function (for example elderly people, people on an angiotensin-converting enzyme inhibitor, angiotensin-II receptor blocker, or another drug that increases the risk of hyperkalaemia, and those with pre-existing renal or hepatic impairment), consider checking renal function and serum electrolytes more frequently.</li><li>If hyperkalaemia develops (potassium greater than 5 mmol/L), stop spironolactone and treat the raised potassium level if appropriate, using clinical judgement.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">National Clinical Guideline Centre, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016o</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field 38919eff-8d7d-4d9a-8380-a71a00cba182 --><!-- end item 38fdf132-f585-453a-822c-a71a00cba2a2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}